Related Experiment Videos
Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue
1Department of Medical Oncology, Chittaranjan National Cancer Institute, Calcutta, India.
Abstract:
As an important enteric neurotransmitter, the role of dopamine as a mitotic inhibitor as well as a protective factor of epithelial cells of stomach and colon indicates its significance in malignant growth of gastrointestinal tract. Our previous results have shown significant alteration of dopamine receptors in human malignant stomach tissues. The present experiments, therefore, evaluate DA content, its receptor expression, and its second-messenger cAMP in human malignant colon tissues to evaluate its role. Results demonstrate a significant decrease of dopamine content, its receptor expression, and its second-messenger cAMP in malignant tissues of human colon. These results may provide insight into the role of dopamine as an enteric neurotransmitter on malignant growth of human colon and may also suggest a therapeutic approach targeting dopamine receptors and its signal transduction.
Insights
Dopamine (DA) levels and its receptor signaling are significantly reduced in human colon cancer tissues. This suggests dopamine
Area of Science:
- Gastroenterology
- Neuroscience
- Oncology
Background:
- Dopamine (DA) acts as an enteric neurotransmitter.
- DA inhibits cell mitosis and protects gastrointestinal epithelial cells.
- Previous studies noted altered dopamine receptors in stomach cancer.
Purpose of the Study:
- To investigate the role of dopamine in colon cancer.
- To evaluate dopamine content, receptor expression, and cAMP levels in malignant colon tissues.
Main Methods:
- Analysis of dopamine content in human colon tissues.
- Assessment of dopamine receptor expression.
- Measurement of cyclic adenosine monophosphate (cAMP) levels.
Main Results:
- Significant decrease in dopamine content in malignant colon tissues.
- Reduced expression of dopamine receptors in cancerous tissues.
- Lower levels of the second messenger cAMP observed.
Conclusions:
- Dopamine signaling is impaired in human colon cancer.
- Reduced dopamine may contribute to colon malignancy.
- Targeting dopamine receptors and signal transduction could offer therapeutic strategies.